

**UNITED STATES DISTRICT COURT
DISTRICT OF MASSACHUSETTS**

OLIVER SHIH, Individually and on Behalf of
All Others Similarly Situated,

Plaintiff, v.

AMYLYX PHARMACEUTICALS, INC.,
JOSHUA B. COHEN, JUSTIN B. KLEE,
JAMES M. FRATES, and MARGARET
OLINGER,

Defendants.

Case No. 1:24-cv-12068-NMG

NOTICE OF PENDENCY AND PROPOSED SETTLEMENT OF CLASS ACTION

Please be advised that your rights may be affected by the above-captioned securities class action (the “Action”) pending in the United States District Court for the District of Massachusetts (the “Court”) if you purchased or otherwise acquired Amylyx Pharmaceuticals, Inc. (“Amylyx” or the “Company”) securities during the period from November 11, 2022, through November 8, 2023, inclusive (the “Settlement Class Period”), and were allegedly damaged thereby (the “Settlement Class”).¹

A federal court authorized this Notice. This is not attorney advertising.

- The Court will hold a hearing on September 10, 2026 at 11:00 a.m. to decide whether to approve the Settlement (the “Final Approval Hearing”). If approved by the Court, the Settlement will provide for the payment of \$6,500,000 gross (the “Settlement Amount”), plus interest as it accrues, minus attorneys’ fees, expenses, compensatory award to Plaintiff, Administrative Costs, and Taxes on interest, to persons and entities who purchased Amylyx securities (NASDAQ ticker symbol: AMLX) during the Settlement Class Period, and who submit eligible Proof of Claim and Release Forms (“Proof of Claim”).
- Based on Plaintiff’s consulting damages expert’s estimate that approximately 27.1 million Amylyx shares have been affected by the conduct alleged in the Action, and assuming that all Settlement Class Members elect to participate in the Settlement, the estimated average gross recovery (before the deduction of any Court-approved fees, expenses and costs as described herein) is approximately \$0.24 per share of Amylyx securities. Settlement Class Members should note, however, that the foregoing average recovery is only an estimate. Settlement Class Members may recover more or less than this amount depending on, among other factors, when their shares were purchased or otherwise acquired and the price at the time of purchase or acquisition; whether the shares were sold and, if so, when they were sold and for how much; and the aggregate value of the Recognized Losses represented by valid and acceptable Proof of Claim forms. In addition, the actual recovery of Settlement Class Members may be further reduced by the payment of fees and costs from the Settlement Fund, as approved by the Court. Distributions to Settlement Class Members will be made based on the Plan of Allocation set forth below (*see* pages 10-12 below) or such other plan of allocation as may be approved by the Court.

¹ All capitalized terms used in this Notice that are not otherwise defined herein have the meanings given to them in the Stipulation of Settlement, dated May 4, 2026 (the “Stipulation”), which is available at www.strategicclaims.net/Amylyx/.

- Attorneys for Plaintiff and the Settlement Class, Pomerantz LLP (“Lead Counsel”), intend to ask the Court to award them fees of up to one-third (33⅓%) of the Settlement Amount, plus interest, and payment of up to \$100,000 in litigation expenses, plus interest, and up to \$-2,500 in total in compensatory award to Plaintiff, pursuant to the Private Securities Action Reform Act of 1995 (“PSLRA”). Since the Action’s inception, Lead Counsel have expended considerable time and effort in this case on a contingent-fee basis and have advanced the expenses of the litigation with the expectation that if they were successful in obtaining a recovery for the Settlement Class, they would be paid from such recovery. Collectively, the requested attorneys’ fees, litigation expenses and compensatory award to Plaintiff are estimated to average approximately \$0.08 per share of Amylyx securities. If approved by the Court, these amounts will be paid from the Settlement Fund.
- The estimated average net recovery, after the deductions set forth in the preceding paragraph, is approximately \$0.16 per share. These estimates are based on the assumptions set forth in the preceding paragraphs. Your actual recovery, if any, will depend on, among other things, when your shares were purchased or otherwise acquired and the price at the time of purchase or acquisition; whether the shares were sold and, if so, when they were sold and for how much; and the aggregate value of the Recognized Losses represented by valid and acceptable Proof of Claim forms.
- The Settlement resolves the Action and Plaintiff’s claims that Amylyx, Joshua B. Cohen, Justin B. Klee, James M. Frates, and Margaret Olinger (collectively, “Defendants”) violated federal securities laws by allegedly making misrepresentations and/or omissions of material fact in public statements to the investing public. Defendants have denied and continue to deny each, any, and all allegations of wrongdoing, fault, liability, or damage whatsoever asserted by Plaintiff.
- The Parties disagree on how much money, if any, could have been won if Plaintiff prevailed on each of his claims.
- For Plaintiff, the principal reason for the Settlement is the guaranteed cash benefit to the Settlement Class. This benefit must be assessed in light of the risk of the uncertain outcome and the risk of any litigation. The Defendants deny that the claims advanced in the Action are meritorious, deny that they have any liability whatsoever to Plaintiff or to any Settlement Class Member, and by entering into this proposed Settlement do not concede the merit of any claims or the lack of merit of any defense to liability. The Defendants have agreed to enter into this proposed Settlement solely to avoid the expense, distraction, time, and uncertainty associated with continuing litigation of the Action.
- If you are a member of the Settlement Class, your legal rights will be affected whether you act or do not act. If you do not act, you may permanently forfeit your right to recover on these claims. Therefore, you should read this Notice carefully.

YOUR LEGAL RIGHTS AND OPTIONS IN THIS SETTLEMENT	
SUBMIT A CLAIM FORM	The only way to get a payment from the Settlement. Proof of Claim forms must be postmarked or submitted online on or before 11:59 p.m. ET August 31, 2026.
EXCLUDE YOURSELF	Get no payment. This is the only option that allows you to ever be part of any other lawsuit against the Defendants or any other Released Parties about the legal claims that were or could have been asserted in this case. Requests for exclusion must be received on or before August 11, 2026.

YOUR LEGAL RIGHTS AND OPTIONS IN THIS SETTLEMENT

OBJECT	Write to the Court about why you do not like the Settlement, the Plan of Allocation, and/or the request for attorneys' fees, costs, and expenses. You will still be a member of the Settlement Class. Objections must be received by the Court and counsel on or before August 24, 2026.
PARTICIPATE IN THE HEARING	Ask to speak in Court about the fairness of the Settlement, the Plan of Allocation, and/or the request for attorneys' fees, costs, and expenses. Requests to speak must be received by the Court and counsel on or before August 24, 2026.
DO NOTHING	Get no payment. Give up your rights.

INQUIRIES

Please do not contact the Court, Defendants, Defendants' Counsel, or the Office of the Clerk of Court regarding this Notice. All inquiries concerning this Notice, the Proof of Claim form, or any other questions by Settlement Class Members should be directed to:

Amylyx Pharmaceuticals, Inc.
Securities Settlement
c/o Strategic Claims Services
600 N. Jackson Street, Suite 205
P.O. Box 230
Media, PA 19063
Telephone: (866) 274-4004
Facsimile: (610) 565-7985
info@strategicclaims.net

or

Jeremy A. Lieberman, Esq.
Samantha Daniels, Esq.
POMERANTZ LLP
600 Third Ave, Floor 20
New York, NY 10016
Telephone: (212) 661-1100
Facsimile: (917) 463-1044
jalieberman@pomlaw.com
sdaniels@pomlaw.com

BASIC INFORMATION CONCERNING THE SETTLEMENT

1. Why did I receive notice of the Settlement?

You or someone in your family may have purchased or otherwise acquired Amylyx securities during the period from November 11, 2022, through November 8, 2023, inclusive (the "Settlement Class Period"). **Receipt of notice does not mean that you are a member of the Settlement Class or that you will be entitled to receive a payment.** If you wish to be eligible for a payment, you are required to submit the Proof of Claim form that is being distributed with this Notice. *See* Question 10 below.

2. What is this case about?

The proposed Settlement resolves the Action known as *Shih v. Amylyx Pharmaceuticals, Inc., et al.*, Case No. 1:24-cv-12068-NMG (D. Mass.). The Court in charge of the case is the United States District Court for the District of Massachusetts. The Action involves allegations that Defendants violated the Securities Exchange Act of 1934 ("Exchange Act"). The operative Amended Class Action Complaint alleges that Defendants made materially false and misleading statements about the success of the launch of AMX0035 (commercially referred to as "Relyvrio" in the U.S.), for the treatment of ALS in adults in the U.S, which artificially inflated the price of Amylyx securities during the Settlement Class Period, and that, when the true facts were revealed, these disclosures caused the price of Amylyx securities to drop, causing harm to members of the Settlement Class.

3. Why is this a class action?

In a class action, one or more persons, called “plaintiffs”, sue on behalf of all persons who have similar claims. All of the persons with similar claims are referred to as a “class”. One court resolves the issues for all class members, except for those who exclude themselves from the class.

4. Why is there a settlement?

Plaintiff and the Defendants do not agree about the merits of Plaintiff’s allegations and the Defendants’ defenses with respect to liability or the average amount of damages per share, if any, that would be recoverable if Plaintiff were to prevail at trial on each claim. The issues on which Plaintiff and the Defendants disagree include: (1) whether the challenged statements were materially false or misleading or otherwise actionable under federal securities laws; (2) whether the Defendants acted with scienter; (3) whether Defendants’ alleged misstatements and omissions caused any damages to investors; (4) the amount of alleged damages, if any, that could be recovered at trial.

This matter has not gone to trial, and the Court has not decided in favor of either Plaintiff or Defendants. Instead, Plaintiff and Defendants have agreed to settle the case. Plaintiff and Lead Counsel believe the Settlement is best for all Settlement Class Members because of the expense and length of continued proceedings necessary to prosecute the Action against Defendants through trial and appeals, as well as the uncertain outcome and the risk of any litigation. Defendants continue to deny each and all of the claims and contentions alleged by Plaintiff and are entering into the Stipulation solely to eliminate the uncertainty, distraction, burden, and expense of further litigation and the length of continued proceedings necessary to defend the Action through trial and appeals.

WHO IS IN THE SETTLEMENT

To see if you will get money from this Settlement, you first have to determine if you are a Settlement Class Member.

5. How do I know if I am part of the Settlement Class?

The Settlement Class consists of all those who purchased or otherwise acquired Amylyx securities between November 11, 2022, and November 8, 2023, inclusive, and who were damaged thereby.

Check your investment records or contact your broker to see if you have any eligible securities. The Parties do not independently have access to your trading information.

6. Are there exceptions to being included?

Yes. Excluded from the Settlement Class are: Defendants; the officers and directors of Amylyx who served in their roles between November 11, 2022 and November 8, 2023; members of their immediate families and their legal representatives, heirs, agents, affiliates, successors or assigns; Defendants’ liability insurance carriers, and any affiliates or subsidiaries thereof; any entity in which Defendants or their immediate families have or had a controlling interest between November 11, 2022 and November 8, 2023. Also excluded from the Settlement Class are any persons or entities who or which exclude themselves by submitting a request for exclusion that is accepted by the Court.

7. What if I am still not sure if I am included?

If you are still not sure whether you are included, you can ask for free help. You can contact the Claims Administrator toll-free at (866) 274-4004 or by email at info@strategicclaims.net or by visiting the website www.strategicclaims.net/Amylyx/, or you can fill out and return the Proof of Claim form available at www.strategicclaims.net/Amylyx/, to see if you qualify.

THE SETTLEMENT BENEFITS – WHAT YOU GET

8. What does the Settlement provide?

The proposed Settlement provides for Defendants to cause the payment of \$6,500,000 into a settlement fund, which may accrue interest (the “Settlement Fund”). The Settlement is subject to Court approval. Also, subject to the Court’s approval, a portion of the Settlement Fund will be used to pay attorneys’ fees with interest and reasonable litigation expenses to Lead Counsel and compensatory awards to Plaintiff. A portion of the Settlement Fund also will be used to pay Taxes due on interest earned by the Settlement Fund, if necessary, and the costs of the claims administration, including the costs of printing and mailing the Post-Card Notice, the costs of publishing notice, and the costs of processing claims. After the foregoing deductions from the Settlement Fund have been made, the amount remaining (the “Net Settlement Fund”) will be distributed to Settlement Class Members who submit timely, valid claims, according to the Plan of Allocation to be approved by the Court (“Authorized Claimants”).

9. How much will my payment be?

Your share of the Net Settlement Fund will depend on several factors, including (i) the date(s) on which you purchased or otherwise acquired Amylyx securities, and the price(s) at the time(s) of purchase or acquisition; (ii) whether you sold Amylyx securities, and if so, the date(s) and price(s) of any such sales; (iii) the Recognized Losses of timely and valid claims submitted by other Settlement Class Members; (iv) the amount of administrative costs, including the costs of notice; and (v) the amount awarded by the Court to Lead Counsel for attorneys’ fees and expenses, and any compensatory award to Plaintiff.

The Claims Administrator will determine each Authorized Claimant’s *pro rata* share of the Net Settlement Fund based upon each Authorized Claimant’s Recognized Loss calculated pursuant to the allocation formulas set forth in the Plan of Allocation approved by the Court. The allocation formula is the basis upon which the Net Settlement Fund will be proportionately allocated to Settlement Class Members with valid claims. The allocation formulas are not intended to estimate the amount that a Settlement Class Member might have been able to recover after a trial; they also are not an estimate of the amount that will be paid to Authorized Claimants pursuant to the Settlement. You can calculate your Recognized Loss by following the instructions in the proposed Plan of Allocation at pages 10-12 of this Notice.

It is unlikely that you will get a payment for all of your Recognized Loss. After all Settlement Class Members have sent in their Proof of Claim forms, the payment you get will be a share of the Net Settlement Fund equal to your proportional share of the Recognized Losses of timely and valid claims submitted by all Authorized Claimants.

HOW YOU GET A PAYMENT—SUBMITTING A CLAIM FORM

10. How can I get a payment?

To qualify for a payment, you must submit a Proof of Claim and Release Form. A copy of the Proof of Claim and Release Form (“Proof of Claim”) is enclosed with this Notice. The Proof of Claim form may also be downloaded from the website for the Settlement, www.strategicclaims.net/Amylyx/, or submitted online using the website claim portal. Read the instructions carefully, fill out the form, include all the documents that the form requests, sign it, and mail or submit it online so that it is postmarked or received **no later than 11:59 p.m. ET on August 31, 2026**. The Proof of Claim may be submitted online at www.strategicclaims.net/Amylyx/ or mailed to:

Amylyx Pharmaceuticals, Inc. Securities Litigation
c/o Strategic Claims Services
600 N. Jackson Street, Suite 205
P.O. Box 230

Media, PA 19063
Fax: (610) 565-7985
info@strategicclaims.net

The Claims Administrator will process your claim and determine whether you are an Authorized Claimant.

11. When would I get my payment?

The Court will hold a Final Approval Hearing on September 10, 2026 at 11:00 a.m. to decide whether to approve the Settlement. If the Court approves the Settlement, there might be appeals afterwards. It is always uncertain whether these appeals can be resolved, and resolving them can take time, perhaps more than a year. It also takes time for all Proof of Claim forms to be processed. Please be patient.

12. What am I giving up to get a payment or to stay in the Settlement Class?

Unless you timely exclude yourself, you will remain a Settlement Class Member and will be bound by the release of claims against the Defendants and the Released Parties. That means you cannot sue, continue to sue, or be part of any other lawsuit against the Defendants or the Released Parties about the Released Claims in this Action. It also means that all of the Court's orders will apply to you and legally bind you, and you will release your claims in this Action against the Defendants and the Released Parties. The specific terms of the release are included in the Stipulation, which is available at www.strategicclaims.net/Amylyx/.

EXCLUDING YOURSELF FROM THE SETTLEMENT CLASS

If you do not want a payment from this Settlement, and you want to keep any right you may have to sue or continue to sue Defendants and the other Released Parties on your own about the claims being released in this Settlement, then you must take steps to remove yourself from the Settlement Class. This is called excluding yourself, or "opting out," from the Settlement Class. Defendants can terminate the Settlement if a certain amount of exclusion requests is received.

13. How do I get out of the proposed Settlement?

To exclude yourself from the Settlement Class, you must mail a letter stating that you request to be "excluded from the Settlement Class in *Shih v. Amylyx Pharmaceuticals, Inc., et al.*, Case No. 1:24-cv-12068-NMG (D. Mass.)." To be valid, the letter must state (A) your name, address, telephone number, and email address (if any); and (B) the number of shares of Amylyx securities that you (i) owned as of the opening of trading on November 10, 2022 and the close of trading on November 8, 2023, and (ii) purchased, acquired, and/or sold between November 11, 2022 and November 8, 2023, inclusive, as well as the dates and prices for each such purchase, acquisition, and sale. Any request for exclusion must be signed and submitted by you, as the beneficial owner. You must submit your exclusion request so that it is **received no later than August 11, 2026 at:**

Amylyx Pharmaceuticals, Inc. Securities Litigation - EXCLUSIONS
c/o Strategic Claims Services
600 N. Jackson Street, Suite 205
P.O. Box 230
Media, PA 19063

You cannot exclude yourself by telephone or by email. If you properly exclude yourself, you will not receive a payment from the Net Settlement Fund, you cannot object to the Settlement, and you will not be legally bound by any orders or the Final Judgment in this case.

14. If I do not exclude myself, can I sue the Defendants or the other Released Parties for the same thing later?

No. Unless you exclude yourself by following the instructions above, you give up any rights to sue the Defendants or the other Released Parties for the claims being released in this Settlement. If you have a pending lawsuit against the Released Parties or related to any Released Claims, speak to your lawyer in that case immediately, since you must exclude yourself from this Settlement Class to continue your own lawsuit. Remember, the exclusion deadline is **August 11, 2026**.

15. If I exclude myself, can I get money from the proposed Settlement?

No. If you exclude yourself, you may not send in a Proof of Claim form to ask for any money from this Settlement.

THE LAWYERS REPRESENTING YOU

16. Do I have a lawyer in this case?

The Court has appointed Pomerantz LLP as Lead Counsel to the Settlement Class, to represent you and the other Settlement Class Members. If you want to be represented by your own lawyer, you may hire one at your own expense and they may file a notice of appearance in the Action. Contact information for Pomerantz LLP is provided above.

17. How will the lawyers be paid?

Lead Counsel have expended considerable time litigating this Action on a contingent-fee basis and have paid for the expenses of the case themselves. They have not been paid attorneys' fees or for their expenses in advance of this Settlement. Lead Counsel have done so with the expectation that, if they are successful in recovering money for the Settlement Class, they will receive attorneys' fees and be paid for their litigation expenses from the Settlement Fund, as is customary in this type of litigation. Lead Counsel will not receive attorneys' fees or be paid for their litigation expenses except from the Settlement Fund. Therefore, Lead Counsel will file a motion prior to the Final Approval Hearing asking the Court for an award of attorneys' fees in an amount not greater than one-third (33⅓%) of the Settlement Fund and payment of litigation expenses of no more than \$100,000, plus interest on such fees and expenses, and for a compensatory award to Plaintiff of no more than \$2,500 in total. The Court may award less than these amounts. Any amounts awarded by the Court will come out of the Settlement Fund.

OBJECTING TO THE SETTLEMENT

18. How do I tell the Court that I object to the proposed Settlement, the Fee and Expense Application, and/or the Plan of Allocation?

If you are a Settlement Class Member, you can tell the Court you do not agree with the proposed Settlement, any part of the Settlement, the proposed Plan of Allocation, and/or Lead Counsel's motion for attorneys' fees and expenses and application for a compensatory award to Plaintiff. You can write to the Court setting out your objection. The Court will consider your views.

To object, you must send a letter saying that you object to the proposed Settlement, Plan of Allocation, and/or application for attorneys' fees and litigation expenses and award to Plaintiff in "*Shih v. Amylyx Pharmaceuticals, Inc., et al.*, Case No. 1:24-cv-12068-NMG (D. Mass.)." You must include (1) your name, address, telephone number, and email address (if any); (2) documentation of all purchases and sales of Amylyx securities during the Settlement Class Period; (3) the objection(s) and the specific reasons for each objection, including whether it applies only to you, to a specific subset of the Settlement Class, or to the entire Settlement Class, and any legal and evidentiary support, and witnesses you wish to bring to the Court's attention; (4) if you are represented by counsel, the name, address, and telephone number of all

counsel, if any, who represent you, including your former or current counsel who may be entitled to compensation in connection with the objection; and (5) the number of times you and your counsel has filed an objection to a class action settlement in the last five years; the nature of each such objection in each case; and the name of the issuer of the security or seller of the product or service at issue in each case.

Attendance at the Final Approval Hearing is not necessary. Objectors wishing to be heard orally at the Final Approval Hearing must indicate in their written objection (or in a separate writing submitted to the counsel listed below no later than seventeen (17) days prior to the Final Approval Hearing) that they intend to participate in the Final Approval Hearing and identify any witnesses they may call to testify or exhibits they intend to introduce into evidence at the Final Approval Hearing. Objectors or their attorneys intending to appear at the Final Approval Hearing must also, no later than seventeen (17) days prior to the Final Approval Hearing, file with the Court, and serve upon counsel listed below, a notice of intention to appear, setting forth the name and address of anyone intending to appear. Any objector or counsel who does not timely file and serve a notice of intention to appear in accordance with this paragraph shall not be permitted to appear, except for good cause shown.

All written objections, papers, and briefs must be submitted to Lead Counsel and Defendants' Counsel at the addresses below such that they are **received no later than August 24, 2026**:

Lead Counsel	Defendants' Counsel
Jeremy A. Lieberman Samantha Daniels, Esq. POMERANTZ LLP 600 Third Avenue, Floor 20 New York, NY 10016 Telephone: (212) 661-1100 Facsimile: (917) 463-1044 jalieberman@pomlaw.com sdaniels@pomlaw.com	Caroline H. Bullerjahn, Esq. GOODWIN PROCTER LLP 100 Northern Avenue Boston, MA 02210 Tel.: 617-570-1000 Fax: 617-523-1231 cbullerjahn@goodwinlaw.com

Lead Counsel will file all objections they receive with the Court.

19. What is the difference between objecting and excluding myself?

Objecting is telling the Court you do not like something about the Settlement or some part of it. You can object only if you stay in the Settlement Class. Requesting exclusion is telling the Court you do not want to be part of the Settlement Class or the Settlement. If you exclude yourself, you cannot object to the Settlement because it no longer concerns you. If you stay in the Settlement Class and object, but your objection is overruled, you will not be allowed a second opportunity to exclude yourself.

THE COURT'S FINAL APPROVAL HEARING

The Court will hold a hearing to decide whether to approve the proposed Settlement, the Fee and Expense Application, and the Plan of Allocation. You may participate, and you may ask to speak, but you do not have to.

20. When and where will the Court decide whether to approve the proposed Settlement?

The Court will hold a Final Approval Hearing, either in person or remotely at the Court's discretion, on September 10, 2026 at 11:00 a.m. at the United States District Court for the District of Massachusetts, John Joseph Moakely United States Courthouse, 1 Courthouse Way, 3rd Floor, Courtroom 4, Suite 2300, Boston, MA 02210.

At this hearing, the Court will consider whether the proposed Settlement is fair, reasonable, and adequate and should be approved by the Court; whether a Judgment as provided for in the Stipulation should be entered; and whether the proposed Plan of Allocation should be approved. If there are objections, the Court will consider them, and the Court will listen to people who have asked to speak at the hearing. The Court may also decide how much should be awarded to Lead Counsel for attorneys' fees and expenses and compensatory award to Plaintiff for his service in representing the Settlement Class.

We do not know how long these decisions will take. You should be aware that the Court may change the date and time of the Final Approval Hearing, or decide to hold it remotely, without another notice being mailed to Settlement Class Members. If you want to attend the hearing, you should check with Lead Counsel or on the Settlement website, www.strategicclaims.net/Amylyx/, beforehand to be sure that the date and/or time has not changed. The Claims Administrator will update the Settlement website in the event that the time or location of the Final Approval Hearing changes.

21. Do I have to come to the hearing?

No. Lead Counsel will answer any questions the Court may have. However, you are welcome to attend at your own expense. If you send an objection, you do not have to come to Court to talk about it. As long as you mail your written objection on time, the Court will consider it. You may also pay your own lawyer to attend, but it is not necessary. Settlement Class Members do not need to appear at the hearing or take any other action to indicate their approval.

22. May I speak at the hearing?

If you object, you may ask the Court for permission to speak at the Final Approval Hearing. To do so, you must include with your objection (see question 18 above) a statement that you “intend to appear in *Shih v. Amylyx Pharmaceuticals, Inc., et al.*, Case No. 1:24-cv-12068-NMG (D. Mass.).” Persons who intend to object to the Settlement, the Plan of Allocation, and/or the application for an award of attorneys' fees, costs, and expenses, and desire to present evidence at the Final Approval Hearing, must include in their written objection the identity of any witnesses they may call to testify and exhibits they intend to introduce into evidence at the Final Approval Hearing. You cannot speak at the hearing if you exclude yourself.

IF YOU DO NOTHING

23. What happens if I do nothing at all?

If you do nothing, you will not receive a payment from the Settlement. However, unless you submit a request for exclusion in accordance with the instructions in the answer to question 13 above, you will not be able to start a lawsuit, continue with a lawsuit, or be part of any other lawsuit against Defendants or the Released Parties about the Released Claims (as defined in the Stipulation) ever again.

GETTING MORE INFORMATION

24. How do I get more information about the case?

This Notice contains only a summary of the terms of the proposed Settlement. For the precise terms and conditions of the proposed Settlement, please see the Stipulation, which is available by visiting the Settlement website at www.strategicclaims.net/Amylyx/ or by contacting the Claims Administrator toll-free at (866) 274-4004. More information about the matters involved in the Action—including, among other documents, the Preliminary Approval Order and the Proof of Claim form—is available at www.strategicclaims.net/Amylyx/. For even more detailed information concerning the matters involved in this Action, see the pleadings filed in the case, the papers filed in support of the Settlement and the Fee and Expense Application, and the orders entered by the Court, which are available for review during business hours at the Office of the Clerk of the Court, United States District Court, District of

Massachusetts, John Joseph Moakely United States Courthouse, 1 Courthouse Way, Boston, MA 02210. (Please check the Court's website, www.nysd.uscourts.gov, for information about Court closures before visiting.) Subscribers to PACER, a fee-based service, can also view the papers filed publicly in the Action through the Court's on-line Case Management/Electronic Case Files system at <https://www.pacer.gov>.

PROPOSED PLAN OF ALLOCATION OF THE NET SETTLEMENT FUND

The Plan of Allocation is a matter separate and apart from the proposed Settlement, and any decision by the Court concerning the Plan of Allocation shall not affect the validity or finality of the proposed Settlement. The Court may approve the Plan of Allocation with or without modifications agreed to among the Parties, or another plan of allocation, without further notice to Settlement Class Members. Any orders regarding a modification of the Plan of Allocation will be posted to the Claims Administrator's website, www.strategicclaims.net/Amylyx/.

The Claims Administrator shall determine the *pro rata* share of the Net Settlement Fund of each Authorized Claimant based upon each Authorized Claimant's Recognized Loss. **Please Note:** The Recognized Loss formula, set forth below, is not intended to be an estimate of the amount of what a Settlement Class Member might have been able to recover after a trial, nor is it an estimate of the amount that will be paid to Authorized Claimants pursuant to the Settlement. The Recognized Loss formula is the basis upon which the Net Settlement Fund will be proportionately allocated to the Authorized Claimants. To the extent there are sufficient funds in the Net Settlement Fund, each Authorized Claimant will receive an amount equal to the Authorized Claimant's Recognized Loss and subject to the provisions in the following paragraphs. If, however, the amount in the Net Settlement Fund is not sufficient to permit payment of the total Recognized Loss of each Authorized Claimant, then each Authorized Claimant shall be paid the percentage of the Net Settlement Fund that each Authorized Claimant's Recognized Loss bears to the total Recognized Losses of all Authorized Claimants and subject to the provisions in the following paragraphs (*i.e.*, "*pro rata* share"). Payment in this manner shall be deemed conclusive against all Authorized Claimants. No distribution will be made on a claim where the potential distribution amount is less than ten dollars (\$10.00) in cash.

If any funds remain in the Net Settlement Fund by reason of uncashed checks, or otherwise, after the Claims Administrator has made reasonable and diligent efforts to have Authorized Claimants who are entitled to participate in the distribution of the Net Settlement Fund cash their distribution checks, then any balance remaining in the Net Settlement Fund six (6) months after the initial distribution of such funds shall be used: (i) first, to pay any amounts mistakenly omitted from the initial distribution to Authorized Claimants; (ii) second, to pay any additional Administrative Costs incurred in administering the Settlement; and (iii) finally, to make a second distribution to Authorized Claimants who cashed their checks from the initial distribution and who would receive at least \$10.00 from such second distribution, after payment of the estimated costs or fees to be incurred in administering the Net Settlement Fund and in making this second distribution, if such second distribution is economically feasible. If six (6) months after such second distribution, if undertaken, or if such second distribution is not undertaken, any funds shall remain in the Net Settlement Fund after the Claims Administrator has made reasonable and diligent efforts to have Authorized Claimants who are entitled to participate in this Settlement cash their checks, any funds remaining in the Net Settlement Fund shall be donated to a non-profit charitable organization(s) agreed upon by the Parties.

THE BASIS FOR CALCULATING YOUR RECOGNIZED LOSS:

Each Authorized Claimant shall be allocated a *pro rata* share of the Net Settlement Fund based on his, her, or its Recognized Loss as compared to the total Recognized Losses of all Authorized Claimants. Recognized Losses will be calculated as follows:

For Amylyx common stock purchased or acquired during the Settlement Class Period, the Recognized Loss shall be calculated as follows:

- A. For shares retained at the end of trading on February 6, 2024, the Recognized Loss shall be the lesser of:
 - (i) \$4.80 per share; or
 - (ii) the difference between the purchase price per share and \$14.54 per share².
- B. For shares sold on or before November 8, 2023, the Recognized Loss per share shall be \$0.00.
- C. For shares sold between November 9, 2023 and February 6, 2024, inclusive, the Recognized Loss shall be the lesser of:
 - (i) \$4.80 per share: or
 - (ii) the difference between the purchase price per share and the average closing price per share as of date of sale provided in Table A below.

Table A										
Date	Closing Price	Average Closing Price		Date	Closing Price	Average Closing Price		Date	Closing Price	Average Closing Price
11/9/2023	\$12.26	\$12.26		12/8/2023	\$14.00	\$13.30		1/9/2024	\$16.40	\$14.11
11/10/2023	\$12.48	\$12.37		12/11/2023	\$14.25	\$13.35		1/10/2024	\$16.16	\$14.16
11/13/2023	\$12.94	\$12.56		12/12/2023	\$14.71	\$13.41		1/11/2024	\$16.22	\$14.20
11/14/2023	\$12.52	\$12.55		12/13/2023	\$14.72	\$13.46		1/12/2024	\$15.79	\$14.24
11/15/2023	\$13.08	\$12.66		12/14/2023	\$14.74	\$13.51		1/16/2024	\$15.52	\$14.27
11/16/2023	\$12.13	\$12.57		12/15/2023	\$14.23	\$13.54		1/17/2024	\$15.08	\$14.29
11/17/2023	\$12.07	\$12.50		12/18/2023	\$14.19	\$13.56		1/18/2024	\$14.88	\$14.30
11/20/2023	\$12.91	\$12.55		12/19/2023	\$13.98	\$13.58		1/19/2024	\$15.01	\$14.31
11/21/2023	\$12.64	\$12.56		12/20/2023	\$13.81	\$13.59		1/22/2024	\$14.69	\$14.32
11/22/2023	\$12.71	\$12.57		12/21/2023	\$13.95	\$13.60		1/23/2024	\$14.61	\$14.33
11/24/2023	\$13.17	\$12.63		12/22/2023	\$14.50	\$13.63		1/24/2024	\$14.37	\$14.33
11/27/2023	\$12.93	\$12.65		12/26/2023	\$14.24	\$13.65		1/25/2024	\$15.37	\$14.35
11/28/2023	\$12.91	\$12.67		12/27/2023	\$14.54	\$13.67		1/26/2024	\$15.38	\$14.37
11/29/2023	\$13.58	\$12.74		12/28/2023	\$14.75	\$13.71		1/29/2024	\$15.79	\$14.39
11/30/2023	\$14.16	\$12.83		12/29/2023	\$14.72	\$13.73		1/30/2024	\$15.62	\$14.42
12/1/2023	\$14.22	\$12.92		1/2/2024	\$14.97	\$13.77		1/31/2024	\$16.00	\$14.44
12/4/2023	\$14.46	\$13.01		1/3/2024	\$16.03	\$13.83		2/1/2024	\$16.57	\$14.48
12/5/2023	\$14.88	\$13.11		1/4/2024	\$16.64	\$13.90		2/2/2024	\$15.78	\$14.50
12/6/2023	\$15.09	\$13.22		1/5/2024	\$16.83	\$13.98		2/5/2024	\$15.30	\$14.52
12/7/2023	\$14.22	\$13.27		1/8/2024	\$16.87	\$14.05		2/6/2024	\$15.56	\$14.54

² Pursuant to Section 21(D)(e)(1) of the Private Securities Litigation Reform Act of 1995, "in any private action arising under this title in which the plaintiff seeks to establish damages by reference to the market price of a security, the award of damages to the plaintiff shall not exceed the difference between the purchase or sale price paid or received, as appropriate, by the plaintiff for the subject security and the mean trading price of that security during the 90-day period beginning on the date on which the information correcting the misstatement or omission that is the basis for the action is disseminated." \$14.54 per share was the mean (average) daily closing trading price of the Company's shares during the 90-day period beginning on November 9, 2023, through and including February 6, 2024.

To the extent a Claimant had a trading gain or “broke even” from his, her, or its overall transactions in Amylyx common stock during the Settlement Class Period, the value of the Recognized Loss will be zero and the Claimant will not be entitled to a share of the Net Settlement Fund. To the extent that a Claimant suffered a trading loss on his, her, or its overall transactions in Amylyx’s common stock during the Settlement Class Period, but that trading loss was less than the Recognized Loss calculated above, then the Recognized Loss shall be limited to the amount of the Claimant’s actual trading loss.

To determine whether a Claimant had a trading gain on his, her, or its overall transactions in Amylyx common stock during the Settlement Class Period, the Claims Administrator will determine the difference between the total amount paid for all shares of Amylyx common stock purchased during the Settlement Class Period, excluding any taxes, fees, or commissions paid on such purchases, minus the total amount received for all such shares of Amylyx common stock sold during the period from November 11, 2022 through the close of trading on February 6, 2024, excluding any taxes, fees, or commissions received for such sales. Any shares of Amylyx common stock purchased during the Settlement Class Period and still held as of the close of trading on February 6, 2024 will be incorporated in the overall calculation as the actual purchase price per share minus \$14.54 per share. Any shares of Amylyx common stock which were held as of the close of trading on November 10, 2022 and sold after the opening of trading on November 11, 2022 (i.e. during the Settlement Class Period or thereafter) will not be included in the overall calculation.

For purposes of calculating your Recognized Loss, the date of purchase, acquisition or sale is the “contract” or “trade” date and not the “settlement” or “payment” date. The receipt or grant by gift, inheritance or operation of law of Amylyx’s common stock shall not be deemed a purchase or acquisition of Amylyx’s common stock for the calculation of an Authorized Claimant’s Recognized Loss. The covering purchase of a short sale is not an eligible purchase. Only publicly traded shares are eligible purchases (Cusip number: 03237H101).

For purposes of calculating your Recognized Loss, all purchases, acquisitions and sales shall be matched on a First In First Out (“FIFO”) basis in chronological order. Therefore, on the Proof of Claim and Release Form enclosed with this Notice, you must provide all of your purchases, acquisitions and sales of Amylyx’s common stock during the time period from November 11, 2022 through and including February 6, 2024.

Payment pursuant to the Plan of Allocation approved by the Court shall be conclusive against all Authorized Claimants. No person shall have any claim against Defendants, Defendants’ Counsel, Lead Plaintiff, Lead Counsel, or the Claims Administrator or other agent designated by Lead Counsel based on the distributions made substantially in accordance with the Stipulation and the Settlement contained therein, the Plan of Allocation, or further orders of the Court. Each Claimant shall be deemed to have submitted to the jurisdiction of the Court with respect to the Claimant’s Proof of Claim and Release Form. All persons involved in the review, verification, calculation, tabulation, or any other aspect of the processing of the claims submitted in connection with the Settlement, or otherwise involved in the administration or taxation of the Settlement Fund or the Net Settlement Fund, shall be released and discharged from any and all claims arising out of such involvement, and all Settlement Class Members, whether or not they are to receive payment from the Net Settlement Fund, will be barred from making any further claim against the Net Settlement Fund beyond the amount allocated to them as provided in any distribution orders entered by the Court.

SPECIAL NOTICE TO SECURITIES BROKERS AND OTHER NOMINEES

If you purchased or otherwise acquired Amylyx securities during the period from November 11, 2022 through November 8, 2023, inclusive, for the beneficial interest of a person or entity other than yourself,

the Court has directed that, **within ten (10) calendar days of your receipt of notice**, you either (a) request the electronic Post-Card Notice or the link to the electronic Notice and Proof of Claim form from the Claims Administrator, and **within ten (10) calendar days of receipt**, email the electronic Post-Card Notice or the link to the electronic Notice and Proof of Claim to all beneficial owners/purchasers for whom valid email addresses are available, (b) request from the Claims Administrator sufficient copies of the Post-Card Notice to forward to all such beneficial owners and, **within ten (10) calendar days of receipt**, forward them to all such beneficial owners, or (c) provide a list of the names, addresses, and email addresses (if any) of all such beneficial owners to the Claims Administrator, in which event the Claims Administrator will promptly mail the Post-Card Notice or email the electronic Post-Card Notice to such identified beneficial owners. If you choose to follow procedure (a) or (b), the Court has directed that, upon such emailing or mailing, you must send a statement to the Claims Administrator confirming that the emailing or mailing was made as directed.

You may request reimbursement from the Settlement Fund for your reasonable out-of-pocket expenses actually incurred in connection with the foregoing, up to a maximum of \$0.02 per link to the Long Notice and Claim Form emailed; \$0.02 per Post-Card Notice, plus postage at the current pre-sort rate used by the Claims Administrator, for Post-Card Notices actually mailed; or \$0.02 per record consisting of name, address, and email address that is provided to the Claims Administrator. Expenses will be paid upon request and submission of appropriate supporting documentation and timely compliance with the above directives. All communications regarding the foregoing should be addressed to the Claims Administrator at the address listed on page 3 above.

DATED: MAY 12, 2026

BY ORDER OF THE UNITED STATES
DISTRICT COURT FOR THE
DISTRICT OF MASSACHUSETTS

PROOF OF CLAIM AND RELEASE FORM

“PROOF OF CLAIM”

Deadline for Submission: August 31, 2026

If you purchased or otherwise acquired Amylyx Pharmaceuticals, Inc. (“Amylyx” or the “Company”) securities during the period from November 11, 2022, through November 8, 2023, inclusive (the “Settlement Class Period”), you may be a “Settlement Class Member” and you may be entitled to share in the Net Settlement Fund. (Excluded from the Settlement Class are Defendants; the officers and directors of Amylyx who served in their role between November 11, 2022 and November 8, 2023; members of their immediate families and their legal representatives, heirs, agents, affiliates, successors or assigns; Defendants’ liability insurance carriers, and any affiliates or subsidiaries thereof; any entity in which Defendants or their immediate families have or had a controlling interest between November 11, 2022 and November 8, 2023; and those persons who exclude themselves by submitting a request for exclusion from the Settlement Class that is accepted by the Court.)

If you are a Settlement Class Member, in order to be eligible for any Settlement benefits, you must complete and submit the electronic version of this Proof of Claim and Release Form (“Proof of Claim”) through the Settlement website at www.strategicclaims.net/Amylyx/ **no later than 11:59 p.m. ET on August 31, 2026**, or you may alternatively complete and sign this Proof of Claim and mail it by first class mail, postmarked **no later than August 31, 2026**, to Strategic Claims Services, the Claims Administrator, at the following address:

Amylyx Pharmaceuticals, Inc. Securities Litigation
c/o Strategic Claims Services
600 N. Jackson St., Suite 205
P.O. Box 230
Media, PA 19063
Tel.: 866-274-4004
Fax: 610-565-7985
info@strategicclaims.net

Your failure to submit your Proof of Claim by August 31, 2026 will subject your claim to rejection and preclude you from receiving any money in connection with the Settlement of this Action. Do not mail or deliver your Proof of Claim to the Court or to any of the parties or their counsel, as any such claim will be deemed not to have been submitted. Submit your claim only to the Claims Administrator. If you are a Settlement Class Member and do not submit a proper Proof of Claim, you will not share in the Settlement, but you nevertheless will be bound by the Final Judgment of the Court unless you exclude yourself. Submission of a Proof of Claim does not assure that you will share in the proceeds of the Settlement.

CLAIMANT'S STATEMENT

1. I (we) purchased or otherwise acquired securities of Amylyx Pharmaceuticals, Inc. ("Amylyx") between November 11, 2022 and November 8, 2023, inclusive ("the Settlement Class Period"). (Do not submit this Proof of Claim if you did not purchase Amylyx securities during the Settlement Class Period.)

2. By submitting this Proof of Claim, I (we) state that I (we) believe in good faith that I am (we are) a Settlement Class Member(s) as defined above and in the Notice of Pendency and Proposed Settlement of Class Action (the "Notice"), or am (are) acting for such person(s); that I am (we are) not a Defendant(s) in the Action or anyone excluded from the Settlement Class; that I (we) have read and understand the Notice; that I (we) believe that I am (we are) entitled to receive a share of the Net Settlement Fund, as defined in the Notice; that I (we) elect to participate in the proposed Settlement described in the Notice; and that I (we) have not filed a request for exclusion. (If you are acting in a representative capacity on behalf of a Settlement Class Member [*e.g.*, as an executor, administrator, trustee, or other representative], you must submit evidence of your current authority to act on behalf of that Settlement Class Member. Such evidence would include, for example, letters testamentary, letters of administration, or a copy of the trust documents.)

3. I (we) consent to the jurisdiction of the Court with respect to all questions concerning the validity of this Proof of Claim. I (we) understand and agree that my (our) claim may be subject to investigation and discovery under the Federal Rules of Civil Procedure, provided that such investigation and discovery shall be limited to my (our) status as a Settlement Class Member(s) and the validity and amount of my (our) claim. No discovery shall be allowed on the merits of the Action or Settlement in connection with processing of the Proof of Claim.

4. I (we) have set forth where requested below all relevant information with respect to each purchase and/or acquisition of Amylyx securities, and each sale, if any, of such securities. I (we) agree to furnish additional information to the Claims Administrator to support this claim if requested to do so.

5. I (we) have provided photocopies or scanned stockbroker's confirmation slips, stockbroker's statements, or other documents evidencing each purchase, acquisition, and sale of Amylyx securities listed below in support of my (our) claim. (IF ANY SUCH DOCUMENTS ARE NOT IN YOUR POSSESSION, PLEASE OBTAIN A COPY OR EQUIVALENT DOCUMENTS FROM YOUR BROKER OR TAX ADVISOR BECAUSE THESE DOCUMENTS ARE NECESSARY TO PROVE AND PROCESS YOUR CLAIM. DO NOT SEND STOCK CERTIFICATES.)

6. I (we) understand that the information contained in this Proof of Claim is subject to such verification as the Claims Administrator may request or as the Court may direct, and I (we) agree to cooperate in any such verification. (The information requested herein is designed to provide the minimum amount of information necessary to process most simple claims. The Claims Administrator may request additional information as required to efficiently and reliably calculate your Recognized Loss. In some cases, the Claims Administrator may condition acceptance of the claim based upon the production of additional information, including, where applicable, information concerning transactions in any derivatives securities such as options.)

7. NOTICE REGARDING ELECTRONIC FILES: Representatives with the authority to file on behalf of (a) accounts of multiple persons and/or (b) institutional accounts with large numbers of transactions ("Representative Filers") must submit information regarding their clients' transactions in the approved electronic spreadsheet format, which is available by request to the Claims Administrator at efile@strategicclaims.net or by visiting the website www.strategicclaims.net/Amylyx/. One spreadsheet may contain the information for multiple persons and institutional accounts, but all Representative Filers MUST also submit a manually signed Proof of Claim, as well as proof of authority to file (see Item 2 of the Claimant's Statement) along with the electronic spreadsheet. Any file not

submitted in accordance with the required electronic filing format will be subject to rejection. No claims submitted in electronic spreadsheet format will be considered to have been properly submitted unless the Claims Administrator issues to the Claimant a written acknowledgment of receipt and acceptance of electronically submitted data. Do not assume that the file has been received or processed until the Claims Administrator sends a confirmation email. If you do not receive such an email within 10 days of submission, please contact the electronic filing department at efile@strategicclaims.net to inquire about the file and confirm it was received and acceptable.

8. NOTICE REGARDING ONLINE FILING: Claimants who are not Representative Filers may submit their claims online using the electronic version of the Proof of Claim hosted at www.strategicclaims.net/Amylyx/. If you are not acting as a Representative Filer, you do not need to contact the Claims Administrator prior to filing; you will receive an automated e-mail confirming receipt once your Proof of Claim has been submitted. If you are unsure if you should submit your claim as a Representative Filer, please contact the Claims Administrator at info@strategicclaims.net or (866) 274-4004. If you are not a Representative Filer, but your claim contains a large number of transactions, the Claims Administrator may request that you also submit an electronic spreadsheet showing your transactions to accompany your Proof of Claim.

I. CLAIMANT INFORMATION

The Claims Administrator will use this information for all communications regarding this Claim Form. If this information changes, you **MUST** notify the Claims Administrator in writing at the address above. Complete names of all persons and entities must be provided.

Beneficial Owner Name		
Joint Beneficial Owner Name		
Address 1 (Street Name and Number)		
Address 2 (apartment, unit, or box number)		
City	State	ZIP
Foreign Province	Foreign Country	
Telephone Number (home)	Telephone Number (work)	
Email Address		
Account Number (if filing for multiple accounts, file a separate Claim Form for each account)		
Social Security Number (for individuals):	OR	Taxpayer Identification Number (for estates, trusts, corporations, etc.):

Claimant Account Type (check appropriate box):

- | | | |
|--|----|--|
| <input type="checkbox"/> Individual (includes joint owner accounts)
<input type="checkbox"/> Corporation
<input type="checkbox"/> IRA/401K | OR | <input type="checkbox"/> Pension Plan <input type="checkbox"/> Trust
<input type="checkbox"/> Estate
<input type="checkbox"/> Other _____ (please specify) |
|--|----|--|

II. SCHEDULE OF TRANSACTIONS IN AMYLYX PHARMACEUTICALS, INC. (“AMYLYX”) SECURITIES

Beginning Holdings:

A. State the total number of shares of Amylyx common stock held at the close of trading on November 10, 2022 (*must be documented*). If none, write “zero” or “0.”

Purchases/Acquisitions:

B. Separately list each and every purchase or acquisition of Amylyx common stock between November 11, 2022 and February 6, 2024, both dates inclusive, and provide the following information (*must be documented*):

Trade Date (List Chronologically) (Month/Day/Year)	Number of Shares Purchased/Acquired	Price per Share	Total Cost (Excluding Commissions, Taxes, and Fees)

Sales:

C. Separately list each and every sale or disposition of Amylyx common stock between November 11, 2022 and February 6, 2024, both dates inclusive, and provide the following information (*must be documented*):

Trade Date (List Chronologically) (Month/Day/Year)	Number of Shares Sold	Price per Share	Amount Received (Excluding Commissions, Taxes, and Fees)

Ending Holdings:

D. State the total number of shares of Amylyx common stock held at the close of trading on February 6, 2024 (*must be documented*).

If additional space is needed, attach separate, numbered sheets, giving all required information, substantially in the same format, and print your name and Social Security or Taxpayer Identification number at the top of each sheet.

III. SUBSTITUTE FORM W-9

Request for Taxpayer Identification Number

Enter taxpayer identification number below for the Beneficial Owner(s). For most individuals, this is your Social Security Number. The Internal Revenue Service (“I.R.S.”) requires such taxpayer identification number. If you fail to provide this information, your claim may be rejected.

Social Security Number (for individuals)	Or	Taxpayer Identification (for estates, trusts, corporations, etc.)

IV. RELEASE

1. I (We) hereby acknowledge full and complete satisfaction of, and do hereby fully, finally, and forever settle, release, relinquish and discharge with prejudice all of the Released Claims against each and all of the Released Parties (as these terms are defined in the Stipulation of Settlement, dated May 4, 2026, the “Stipulation”).

2. I (We) hereby acknowledge that I (we) will not be entitled to bring, or receive recovery in, any other action against any of the Released Parties based on or arising out of the Released Claims (as these terms are defined in the Stipulation).

3. This Release shall be of no force or effect unless and until the Court approves the Settlement and it becomes effective on the Effective Date.

4. I (We) hereby warrant and represent that I (we) am (are) a member of the Settlement Class and I (we) have not assigned or transferred or purported to assign or transfer, voluntarily or involuntarily, any matter released pursuant to this release or any other part or portion thereof.

V. CERTIFICATION

I (We) submit this Proof of Claim under the terms of the Stipulation described in the Internet Notice. I (We) also submit to the jurisdiction of the United States District Court for the District of Massachusetts with respect to my (our) claim as a Settlement Class Member(s) and for purposes of enforcing the release and covenant not to sue set forth herein. I (We) further acknowledge that I am (we are) bound by and subject to the terms of any judgment that may be entered in this Action. I (We) have not submitted any other claim covering the same purchases or sales of Amylyx securities during the Settlement Class Period and know of no other person having done so on my (our) behalf.

I (We) certify that I am (we are) NOT subject to backup withholding under the provisions of Section 3406(a)(1)(c) of the Internal Revenue Code because: (a) I am (We are) exempt from backup withholding; or (b) I (We) have not been notified by the I.R.S. that I am (we are) subject to backup withholding as a result of a failure to report all interest or dividends; or (c) the I.R.S. has notified me (us) that I am (we are) no longer subject to backup withholding.

NOTE: If you have been notified by the I.R.S. that you are subject to backup withholding, please strike out the language that you are not subject to backup withholding in the certification above.

UNDER THE PENALTIES OF PERJURY UNDER THE LAWS OF THE UNITED STATES, I (WE) CERTIFY THAT ALL OF THE INFORMATION I (WE) PROVIDED ON THIS PROOF OF CLAIM

AND RELEASE FORM IS TRUE, CORRECT, AND COMPLETE, AND I (WE) AGREE TO BE BOUND BY ALL ORDERS ENTERED IN THE ACTION.

Signature of Claimant (If this claim is being made on behalf of Joint Claimants, then each must sign):

(Signature)

(Signature)

(Capacity of person(s) signing, e.g. beneficial purchaser(s), executor, administrator, trustee, etc.)

Check here if proof of authority to file is enclosed.
(See Item 2, above)

You should be aware that it will take a significant amount of time to process fully all of the Proof of Claims and to administer the Settlement. This work will be completed as promptly as time permits, given the need to investigate and tabulate each Proof of Claim. Please notify the Claims Administrator of any change of address.

REMINDER CHECKLIST

- Please be sure to sign this Proof of Claim and Release Form on page 7. If this Proof of Claim and Release Form is submitted on behalf of joint claimants, then both claimants must sign.
- Please remember to attach or scan supporting documents. Do NOT send any stock certificates. Keep copies of everything you submit.
- Do NOT use highlighter on the Proof of Claim and Release Form or any supporting documents.
- If you move or change your address, telephone number, or email address, please submit the new information to the Claims Administrator, as well as any other information that will assist us in contacting you. NOTE: Failure to submit updated information to the Claims Administrator may result in the Claims Administrator's inability to contact you regarding issues with your claim or to deliver payment to you.

THIS PAGE INTENTIONALLY LEFT BLANK

Amylyx Pharmaceuticals, Inc. Securities Litigation
c/o Strategic Claims Services
600 N. Jackson St., Suite 205
Media, PA 19063

IMPORTANT LEGAL NOTICE – PLEASE FORWARD